Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Randomized Parallel Two-arm Multicenter Study of Eribulin Versus Vinorelbine in Female Subjects With Locally Recurrent or Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane

Next Previous
Trial Profile

An Open-label Randomized Parallel Two-arm Multicenter Study of Eribulin Versus Vinorelbine in Female Subjects With Locally Recurrent or Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eribulin (Primary) ; Vinorelbine
  • Indications Advanced breast cancer; Carcinoma
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Sponsors Eisai Co Ltd

Most Recent Events

  • 13 Sep 2022 Results of post-hoc analysis of three trials (NCT00388726, NCT00337103 and NCT02225470) assessing efficacy of eribulin mesylate in HER2-low metastatic breast cancer, presented at the 47th European Society for Medical Oncology Congress
  • 10 Sep 2022 Results of post-hoc analysis published in the Eisai Inc Media Release.
  • 10 Sep 2022 According to an Eisai Inc media release, results from a post-hoc analysis of three trials (NCT00388726, NCT00337103 and NCT02225470) were presented as a poster (Presentation: #259P) at the European Society for Medical Oncology (ESMO) Annual Meeting (#ESMO22).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top